Metabolic response of soy pinitol on lipid-lowering, antioxidant and hepatoprotective action in hamsters fed-high fat and high cholesterol diet

Molecular Nutrition and Food Research

Volumn 53, Issue 6, 2009, Pages 751-759

  Choi, Myung Sook ^a   Lee, Mi Kyung ^b   Jung, Un Ju ^a   Kim, Hye Jin ^a   Do, Geoyng Min ^a   Park, Yong Bok ^a   Jeon, Seon Min ^a  

^a Kyungpook National University   (South Korea)

^b Sunchon National University   (South Korea)

Author keywords

Hamster; Hepatoprotection; High fat and high cholesterol diet; Lipid and antioxidant metabolism; Soy pinitol

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; DRUG DERIVATIVE; INOSITOL; LIPID; PINITOL;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; CHEMISTRY; CHOLESTEROL INTAKE; DRUG EFFECT; EATING; FAT INTAKE; HAMSTER; LIPID PEROXIDATION; LIVER; MALE; METABOLISM; ORGAN SIZE; SOYBEAN; SYRIAN HAMSTER;

ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; BODY WEIGHT; CHOLESTEROL, DIETARY; CRICETINAE; DIETARY FATS; EATING; INOSITOL; LIPID PEROXIDATION; LIPIDS; LIVER; MALE; MESOCRICETUS; ORGAN SIZE; SOYBEANS;

CRICETINAE;

EID: 67651040885     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200800241     Document Type: Article

References (46)

1. Larner, J., Allan, G., Kessler, C., Reamer, P., et al., Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy, J. Basic Clin. Physiol. Pharmacol. 1998, 9, 127-137.
2. Huang, L. C., Heimark, D., Linko, J., Nolan, R., Larner, J., A model phosphatase 2C fi phosphatase 1 activation cascade via dual control of inhibitor-1 (INH-1) and DARPP-32 dephosphorylation by two inositol glycan putative insulin mediators from beef liver, Biochem. Biophys. Res. Commun. 1999, 255, 150-156.
3. Müller, G., Wied, S., Crecelius, A., Kessler, A., Eckel, J., Phosphoinositol-glycan-peptides from yeast potently induce metabolic insulin actions in isolated rat adipocytes, cardiomyocytes, and diaphragms, Endocrinology 1997, 138, 3459-3475.
4. Fonteles, M. C., Huang, L. C., Larner, J., Infusion of pH 2.0 D-chiro-inositol glycan insulin putative mediator normalizes plasma glucose in streptozotocin diabetic rats at a dose equivalent to insulin without inducing hypoglycaemia, Diabetologia 1996, 39, 731-734.
5. Ostlund, R., Sherman, W., Pinitol and derivatives thereof for the treatment of metabolic disorders, US Patent No. 5550166, 1996.
6. Bates, S. H., Jones, R. B., Bailey, C. J., Insulin-like effect of pinitol, Br. J. Pharmacol. 2000, 130, 1944-1948.
7. Weeks, C., Stimulating transport of glucose into animal administration of pinitol, US Patent No. 6518318, 2003.
8. Ortmeyer, H., Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant Rhesus Monkeys, Obes. Res. 1996, 4, 569-575.
9. Choi, M. S., Lee, W. H., Kwon, E. Y., Kang, M. A., et al., Effects of soy pinitol on the pro-inflammatory cytokines and scavenger receptors in oxLDL-treated THP-1 macrophages, J. Med. Food 2007, 10, 594-601.
10. Do, G. M., Choi, M. S., Kim, H. J., Woo, M. N., et al., Soy pinitol acts partly as an insulin sensitizer or insulin mediator in 3T3-L1 preadipocytes, Genes Nutr. 2008, 2, 359-364.
11. Zou, Y., Li, J., Lu, C., Wang, J. et al., High-fat emulsioninduced rat model of nonalcoholic steatohepatitis, Life Sci. 2006, 79, 1100-1107.
12. Spady, D. K., Strange, E. F., Bilhartz, L. E., Dietschy, J. M., Bile acids regulate hepatic low-density lipoprotein receptor activity in the hamster by altering cholesterol flux across the liver, Proc. Natl. Acad. Sci. USA 1986, 83, 1916-1920.
13. Mackness, M. I., Arrol, S., Durrington, P. N., Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein, FEBS Lett. 1991, 286, 152-154.
14. Folch, J., Lees, M., Sloane-Stanley, G. H., A simple method for isolation and purification of total lipids from animal tissues, J. Biol. Chem. 1957, 226, 497-509.
15. Hulcher, F. H., Oleson, W. H., Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A, J. Lipid Res. 1973, 14, 625-631.
16. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 1976, 72, 248-254.
17. Shapiro, D. J., Nordstrom, J. L., Mitschelen, J. J., Rodwell, V. W., Schimke, R. T., Microassay for 3-hydroxy-3-methylglutaryl CoA reductase in rat liver and in L-cell fibroblast, Biochim. Biophys. Acta 1974, 370, 369-377.
18. Gillies, P. J., Rathgeb, K. A., Robinson, C. S., Regulation of acyl-CoA:cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: Role of a cholesterol substrate pool, Exp. Mol. Pathol. 1986, 44, 320-339.
19. Koop, D. R., Hydroxylation of q-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a, Mol. Pharmacol. 1986, 29, 399-404.
20. Marklund, S., Marklund, G., Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase, Eur. J. Biochem. 1974, 47, 469-474.
21. Aebi, H., Catalase. Method of Enzymatic Analysis, Vol. 2, Academic Press, New York 1974, pp. 673-684.
22. Paglia, E. D., Valentine, W. N., Studies on the quantitative and qualitative characterization of erythrocytes glutathione peroxidase, J. Lab. Clin. Med. 1979, 70, 158-169.
23. Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction, Anal. Biochem. 1979, 95, 351-358.
24. Wolff, S. P., Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides, Methods Enzymol. 1994, 233, 182-189.
25. Kim, J. I., Kim, J. C., Kang, M. J., Lee, M. S., et al., Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: A randomized controlled study, Eur. J. Clin. Nutr. 2005, 59, 1-3.
26. Kinosian, B., Glick, H., Garland, G., Cholesterol and coronary heart disease: Predicting risks by levels and ratios, Ann. Int. Med. 1994, 121, 641-647.
27. Miller, N. E., Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis, Am. Heart J. 1987, 113, 589-597.
28. Sorenson, R. C., Bisgaier, C. L., Aviram, M., Hsu, C., et al., Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity, Arterioscler. Thromb. Vasc. Biol. 1999, 19, 2214-2225.
29. Mackness, M. I., Mackness, B., Durrington, P. N., Fogelman, A. M. et al., Paraoxonase and coronary heart disease, Curr. Opin. Lipidol. 1998, 9, 319-324.
30. Saha, N., Roy, A. C., Teo, S. H., Tey, J. S. H., Ratnam, S. S., Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins, Clin. Genet. 1991, 40, 277-282.
31. Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., et al., Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants, Free Radic. Biol. Med. 1999, 26, 892-904.
32. Jeon, S. M., Park, Y. B., Kwon, O. S., Huh, T. L., et al., Vitamin E supplementation alters HDL-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: Comparison with probucol., J. Biochem. Mol. Toxicol. 2005, 19, 336-346.
33. Nobre, H. V., Jr., Cunha, G. M., Moraes, M. O., Luciana, M. F., et al., Quebrachitol (2-O-methyl-L-inositol) attenuates 6-hydroxydopamine-induced cytotoxicity in rat fetal mesencephalic cell cultures, Food Chem. Toxicol. 2006, 44, 1544-1551.
34. Hong, J., Pan, J., Gonzalez, F. J., Gelboin, H. V., Yang, C. S., The induction of a specific form of cytochrome P450 (P450j) by fasting, Biochem. Biophys. Res. Commun. 1987, 142, 1077-1083.
35. Dong, Z., Hong, J., Ma, Q., Li, D., et al., Mechanismof induction of cytochrome P450ac(P450j) in chemically-induced and spontaneously diabetic rats, Arch. Biochem. Biophys. 1988, 263, 29-35.
36. Singh, R. K., Pandey, B. L., Tripathi, M., Pandey, V. B., Antiinflammatory effect of (+)-pinitol, Fitoterapia 2001, 72, 168-170.
37. Terauchi, Y., Takamoto, I., Kubota, N., Matsui, J., et al., Glucokinase and IRS-2 are required for compensatory β cell hyperplasia in response to high-fat diet-induced insulin resistance, J. Clin. Invest. 2007, 117, 246-257.
38. Evans, D. J., Murray, R., Kissebah, A. H., Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography, J. Clin. Invest. 1984, 74, 1515-1525.
39. Boden, G., Role of fatty acids in the pathogenesis of insulin resistance and NIDDM, Diabetes 1997, 46, 3-10.
40. Després, J. P., Lamarche, B., Mauriège, P., Cantin, B., et al., Hyperinsulinemia as an independent risk factor for ischemic heart disease, N. Engl. J. Med. 1996, 334, 952-957.
41. Cruz, M. L., Shaibi, G. Q., Weigensberg, M. J., Spruijt-Metz, D., et al., Pediatric obesity and insulin resistance: Chronic disease risk and implications for treatment and prevention beyond body weight modification, Annu. Rev. Nutr. 2005, 25, 435-468.
42. Smith, S. R., De Jonge, L., Volaufova, J., Li, Y., et al., Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial, Metabolism 2005, 54, 24-32.
43. Foellmi-Adams, L. A., Wyse, B. M., Herron, J., Nedergaard, J., Kletzein, R. F., Induction of uncoupling protein in brown adipose tissue. Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent, Biochem. Pharmacol. 1996, 52, 693-701.
44. Hotamisligil, G. S., Shargill, N. S., Spiegelman, B. M., Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance, Science 1993, 259, 87-91.
45. Pajvani, U. B., Du, X., Combs, T. P., Berg, A. H., et al., Structurefunction studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity, J. Biol. Chem. 2003, 278, 9073-9085.
46. Weiss, R., Dufour, S., Taksali, S., Tamborlane, W., et al., Prediabetes in obese youth: A syndrome of impaired glucose tolerance, severe insulin resistance and altered myocellular and fat partitioning, Lancet 2003, 362, 951-957.